Wang M, et al. - In this cross-sectional study, researchers examined the relationship between circulating C1q/tumor necrosis factor-related protein-6 (CTRP6) with type 2 diabetes mellitus (T2DM). The findings from the present study suggested that CTRP6 may be a metabolism- and nutrition-related adipokine and might be related to insulin resistance and T2DM.

Methods

• For this investigation, researchers involved 118 patients with newly diagnosed T2DM, 98 subjects with impaired glucose tolerance (IGT) and 132 healthy subjects.
• They performed oral glucose tolerance tests (OGTT) in 48 healthy people to examine the relationship of CTRP6 with glucose, insulin and other adipokines.
• By ELISA, circulating CTRP6, tumor necrosis factor-α (TNF-α) and adiponectin (Adipoq) were measured.

Results

• Study results showed that IGT and T2DM individuals had higher serum CTRP6 levels than healthy controls (406.2 ± 136.6 and 539.1 ± 169.7 vs. 354.3 ± 117.2 ng/mL; both P < 0.01).
• Compared with IGT individuals (P < 0.01), serum CTRP6 concentrations were further increased in T2DM patients.
• Data reported that serum CTRP6 levels were found to be related positively to body mass index, waist-to-hip ratio, the percentage of body fat, total cholesterol, triglycerides, HbA1c, fasting blood glucose, 2-hour blood glucose after glucose overload, fasting insulin, 2 h-Ins, homeostasis model assessment of insulin resistance, and TNF-α.
• In addition, serum CTRP6 levels were found to be related negatively with high-density lipoprotein cholesterol and Adipoq in all individuals (P < 0.05 or P < 0.01).
• According to the multivariate logistic regression analysis, CTRP6 was associated with both IGT and T2DM.
• Serum CTRP6 concentrations showed a similar change with blood glucose, insulin, TNF-α and Adipoq after an oral glucose challenge.